Hypertension, Dyslipidemia Among Patients With HIV On ART Associated With Use Of INSTIs Or Tenofovir Alafenamide, Study Finds

Infectious Disease Advisor (6/10, Nye) reports, “In patients with HIV infection on antiretroviral therapy, associations were observed between gain, the concurrent or separate use of integrase strand transfer inhibitors [INSTIs] or tenofovir alafenamide, and incident hypertension and dyslipidemia risk.” In the study, “dyslipidemia incidence was higher among patients on INSTIs with TAF, INSTIs without TAF, or TAF without INSTIs (IR, 161, 139, and 157 per 1000 person-years, respectively) than in those on ART regimens without INSTIs or TAF (IR, 129 per 1000 person-years).” Meanwhile, “hypertension risk was associated with the use of INSTIs with TAF (adjusted IRR, 1.48; 95% CI, 1.31-1.68), TAF without INSTIs (aIRR, 1.33; 95% CI, 1.14-1.55), and INSTIs without TAF (aIRR, 1.25; 95% CI, 1.13-1.39).” These results were published in The Lancet HIV.